Side-by-side · Research reference
N-Acetyl Epitalon AmidatevsSS-31
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED12/45 cited
BPhase 3HUMAN-REVIEWED9/43 cited
N-Acetyl Epitalon Amidate
Bioregulator Tetrapeptide · Khavinson School
SQ · Variable protocols
SS-31
Cardiolipin-binding · Mitochondrial protective
SQ · Abdomen · Once daily
01Mechanism of Action
Parameter
N-Acetyl Epitalon Amidate
SS-31
Primary target
DNA promoter regions (telomerase, RNA polymerase II, retinal genes)
Cardiolipin in inner mitochondrial membraneSzeto 2014
Pathway
Peptide → DNA complementary binding → Gene transcription initiation → Telomerase catalytic subunit expression
Cardiolipin binding → cristae stabilisation → ETC integrity → reduced ROS + preserved ATP synthesisSzeto 2014Szilagyi 2009
Downstream effect
Telomerase enzymatic activity induction, telomere elongation to early-passage length, extension of replicative lifespan in human somatic cellsKhavinson 2003Khavinson 2004
Mitochondrial bioenergetic preservation; cardio-, neuro-, and reno-protective effects in animal + clinical studiesSzeto 2014
Feedback intact?
—
—
Origin
Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from pineal extract bioregulator research; N-acetyl and C-amide modifications enhance plasma stability
Synthetic tetrapeptide D-Arg-Dmt-Lys-Phe-NH₂; cell-permeable, mitochondrial-selectiveSzeto 2014
Antibody development
—
—
02Dosage Protocols
Parameter
N-Acetyl Epitalon Amidate
SS-31
Standard dose
No standardized human dosing in indexed literature
In vitro protocols use direct culture addition; human clinical dosing protocols are in Russian-language literature outside PubMed scope.
40 mg / day SQ (clinical trials)Szeto 2014
Anecdotal community range 5-10 mg/day. Phase 3 trials use 40 mg.
Frequency
Not specified in candidate papers
Once daily
Evidence basis
In vitro human cell cultureKhavinson 2004Khavinson 2003
Multiple Phase 3 trials (Barth, AMD, ischemia-reperfusion)Szeto 2014Szilagyi 2009
Cell culture protocol
Addition to human fetal fibroblast culture induced telomerase activity and telomere elongation to early-passage lengthKhavinson 2004
Cells made 10 extra divisions (44 passages total vs 34 in control).
—
Duration
Chronic treatment in aging culture
Sustained effect through late passages.
Indefinite for mitochondrial disease; cycled for healthspan use
Modification stability
N-acetyl + C-amide caps enhance peptidase resistance
Standard strategy for tetrapeptide stabilization; specifics not quantified in candidates.
—
Lower / starter dose
—
5 mg / day (anecdotal)
Reconstitution
—
Bacteriostatic water
Timing
—
Morning fasted preferred; pre-workout for exercise-induced mitochondrial stress
Half-life
—
~3 h plasma; tissue uptake longer
04Side Effects & Safety
Parameter
N-Acetyl Epitalon Amidate
SS-31
Human safety data
Not available in indexed literature
Candidate papers describe in vitro and animal models only.
—
Theoretical telomerase risk
Telomerase activation in somatic cells raises theoretical oncogenic transformation concern
—
Injection site reaction
—
Erythema, mild pruritus
GI symptoms
—
Nausea (uncommon)
Headache
—
Reported in some Phase 3 trials
Cardiovascular
—
Cardio-protective in studies; no signal of harm
Pregnancy / OB
—
Avoid — insufficient data
Absolute Contraindications
N-Acetyl Epitalon Amidate
- ·Active malignancy or history of cancer — telomerase reactivation may promote tumor cell immortalization
SS-31
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to peptide
Relative Contraindications
N-Acetyl Epitalon Amidate
- ·Individuals with hereditary cancer syndromes or high genetic cancer risk
SS-31
- ·None established
05Administration Protocol
Parameter
N-Acetyl Epitalon Amidate
SS-31
1. Route
Subcutaneous injection assumed based on peptide class; no specific protocol in candidate papers.
Add bacteriostatic water per label. Light-protected handling.
2. Reconstitution
Standard bacteriostatic water for lyophilized peptides. Exact volume not specified in indexed literature.
SQ — abdomen or thigh. Rotate sites.
3. Storage
Lyophilized: -20 °C, desiccated. Reconstituted: refrigerate 2–8 °C. N-acetyl and C-amide modifications improve stability vs unprotected tetrapeptide.
Morning fasted; pre-workout for exercise-augmented mitochondrial stress.
4. Clinical protocols
Human dosing schedules published in Russian-language clinical literature; not indexed in PubMed candidate set.
Lyophilised: refrigerate, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle
—
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
N-Acetyl Epitalon Amidate
+ Thymalin
ModerateBoth are Khavinson-school bioregulators with epigenetic mechanisms. Thymalin targets thymic transcription factors for immune function, while Epitalon targets telomerase and pineal-axis genes. Combined use theoretically addresses dual axes of aging: replicative senescence and immune decline. Multi-target bioregulator strategy per Khavinson gerontology framework.
- Epitalon
- Protocol not defined in indexed literature
- Thymalin
- Tissue-specific bioregulator · separate dosing
- Rationale
- Complementary transcriptional targets
- Primary benefit
- Dual-axis aging intervention: cellular senescence + immune restoration
SS-31
+ MOTS-c
ModerateSS-31 and MOTS-c address mitochondrial decline through complementary axes. SS-31 protects existing mitochondrial structure (cardiolipin binding, cristae stabilisation). MOTS-c upregulates AMPK/PGC-1α, triggering biogenesis of new mitochondria. Together they pair preservation with renewal — anecdotally favoured in healthspan and post-cardio-event recovery protocols.
- SS-31
- 5–10 mg SQ · daily morning
- MOTS-c
- 5 mg SQ · 2× per week pre-workout
- Primary benefit
- Mitochondrial preservation + biogenesis